Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 23884071)

1.

Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.

Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S80-9. doi: 10.1093/cid/cit306. Review.

2.
3.

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S129-37. doi: 10.1093/cid/cit302.

4.

Hepatitis C virus reinfection following treatment among people who use drugs.

Grady BP, Schinkel J, Thomas XV, Dalgard O.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S105-10. doi: 10.1093/cid/cit301. Review.

5.

Reinfection with hepatitis C virus following sustained virological response in injection drug users.

Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, Gallagher L, Krajden M, Dore GJ, Duncan F, Conway B.

J Gastroenterol Hepatol. 2010 Jul;25(7):1281-4. doi: 10.1111/j.1440-1746.2010.06238.x.

PMID:
20594256
6.

Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH.

Clin Infect Dis. 2013 Mar;56(6):806-16. doi: 10.1093/cid/cis1007. Epub 2012 Dec 7. Review.

7.

Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial.

Reimer J, Schmidt CS, Schulte B, Gansefort D, Gölz J, Gerken G, Scherbaum N, Verthein U, Backmund M.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S97-104. doi: 10.1093/cid/cit307.

8.

Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH.

World J Gastroenterol. 2013 Nov 28;19(44):7846-51. doi: 10.3748/wjg.v19.i44.7846. Review.

9.

Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.

Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK.

Med J Aust. 2012 Jun 4;196(10):638-41.

PMID:
22676879
10.

The cost-effectiveness of testing for hepatitis C in former injecting drug users.

Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.

Health Technol Assess. 2006 Sep;10(32):iii-iv, ix-xii, 1-93.

11.

A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.

Hagan H, Pouget ER, Des Jarlais DC.

J Infect Dis. 2011 Jul 1;204(1):74-83. doi: 10.1093/infdis/jir196. Review.

12.

Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam.

Grady BP, Vanhommerig JW, Schinkel J, Weegink CJ, Bruisten SM, Lindenburg CE, Prins M.

Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1302-7.

PMID:
22825643
13.
14.

Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe.

Palmateer NE, Hutchinson SJ, Innes H, Schnier C, Wu O, Goldberg DJ, Hickman M.

Int J Drug Policy. 2013 Mar;24(2):85-100. doi: 10.1016/j.drugpo.2012.08.006. Epub 2012 Sep 29. Review.

PMID:
23026541
15.

HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.

Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M.

J Viral Hepat. 2015 Apr;22(4):399-408. doi: 10.1111/jvh.12338. Epub 2014 Oct 7.

16.

Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow.

McDonald SA, Hutchinson SJ, Cameron SO, Innes HA, McLeod A, Goldberg DJ.

Int J Drug Policy. 2012 Sep;23(5):353-7. doi: 10.1016/j.drugpo.2012.02.003. Epub 2012 Mar 14.

PMID:
22421553
17.

Hepatitis C virus vaccines among people who inject drugs.

Cox AL, Thomas DL.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S46-50. doi: 10.1093/cid/cit329. Review.

18.

Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.

Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, Hutchinson SJ, Hellard ME.

Int J Drug Policy. 2014 Jan;25(1):179-82. doi: 10.1016/j.drugpo.2013.08.005. Epub 2013 Sep 8.

PMID:
24315504
19.

Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.

MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, Taylor A, Roy K, Aspinall E, Goldberg D, Rhodes T, Hedrich D, Salminen M, Hickman M, Hutchinson SJ.

Int J Drug Policy. 2014 Jan;25(1):34-52. doi: 10.1016/j.drugpo.2013.07.001. Epub 2013 Aug 21. Review.

PMID:
23973009
20.

Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012.

Grebely J, Lima VD, Marshall BD, Milloy MJ, DeBeck K, Montaner J, Simo A, Krajden M, Dore GJ, Kerr T, Wood E.

PLoS One. 2014 Jun 4;9(6):e97726. doi: 10.1371/journal.pone.0097726. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk